Cargando…

PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”

Prostate cancer (PCa) is the second leading cause of malignancy-related mortality in males in the Western world. Although treatment like prostatectomy and radiotherapy for localized cancer have good results, similar positive outcomes are not achieved in metastatic PCa. Consequently, these aggressive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zuccolotto, Gaia, Penna, Alessandro, Fracasso, Giulio, Carpanese, Debora, Montagner, Isabella Monia, Dalla Santa, Silvia, Rosato, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511814/ https://www.ncbi.nlm.nih.gov/pubmed/34660275 http://dx.doi.org/10.3389/fonc.2021.708073

Ejemplares similares

Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2020)

PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models
por: Zuccolotto, Gaia, et al.
Publicado: (2014)

T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression
por: Kegler, Alexandra, et al.
Publicado: (2019)

Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2015)

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2020)

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma
por: Ying, Zhitao, et al.
Publicado: (2019)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
por: Ferreira, Leonardo M. R., et al.
Publicado: (2021)

The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells
Publicado: (1991)

Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment
por: Ma, Haili, et al.
Publicado: (2017)

Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells
por: Nguyen, Phuong, et al.
Publicado: (2020)

CD28(−) and CD28(low)CD8(+) Regulatory T Cells: Of Mice and Men
por: Vuddamalay, Yirajen, et al.
Publicado: (2017)

Anti‐CLL1‐based CAR T‐cells with 4‐1‐BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia
por: Pei, Kunlin, et al.
Publicado: (2023)

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
por: Baroni, Matteo Libero, et al.
Publicado: (2020)

CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus
por: Textor, Ana, et al.
Publicado: (2021)

4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells
por: Roselli, Emiliano, et al.
Publicado: (2021)

Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions
por: Meng, Xianhui, et al.
Publicado: (2020)

ERK Activation in CAR T Cells Is Amplified by CD28-Mediated Increase in CD3ζ Phosphorylation
por: Rohrs, Jennifer A., et al.
Publicado: (2020)

Correction: 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Publicado: (2020)

CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
por: Saoulli, Katina, et al.
Publicado: (1998)

Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors
por: Feucht, J., et al.
Publicado: (2020)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells
por: Mezősi-Csaplár, Marianna, et al.
Publicado: (2023)

Triggering of lymphocytes by CD28, 4-1BB, and PD-1 checkpoints to enhance the immune response capacities
por: Kaviani, Elina, et al.
Publicado: (2022)

Stimulation of CD28 triggers an association between CD28 and phosphatidylinositol 3-kinase in Jurkat T cells
Publicado: (1994)

Association of CD28 IVS3 +17T/C Polymorphism with Soluble CD28 in Rheumatoid Arthritis
por: Ledezma-Lozano, I. Y., et al.
Publicado: (2011)

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
por: Lorenzini, Theo, et al.
Publicado: (2023)

Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells
Publicado: (1992)

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

CD28, Costimulator or Agonist Receptor?
por: Margulies, David H.
Publicado: (2003)

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation
por: Halim, Leena, et al.
Publicado: (2022)

Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function
por: Blaeschke, Franziska, et al.
Publicado: (2022)

Restoration of CD28 Expression in CD28(−) CD8(+) Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production
por: Topp, Max S., et al.
Publicado: (2003)

The Role of CD28 and CD8(+) T Cells in Keloid Development
por: Shan, Mengjie, et al.
Publicado: (2022)

Peritoneal Tumor Carcinomatosis: Pharmacological Targeting with Hyaluronan-Based Bioconjugates Overcomes Therapeutic Indications of Current Drugs
por: Montagner, Isabella Monia, et al.
Publicado: (2014)

Decreased CD8(+)CD28(+)/CD8(+)CD28(–) T cell ratio can sensitively predict poor outcome for patients with complicated Crohn disease
por: Dai, Shi-xue, et al.
Publicado: (2017)

CD3(+)CD8(+)CD28(−) T Lymphocytes in Patients with Lupus Nephritis
por: Żabińska, Marcelina, et al.
Publicado: (2016)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells
por: Guercio, Marika, et al.
Publicado: (2020)

Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines
por: Dalla Pietà, Anna, et al.
Publicado: (2021)

CD28 signals through acidic sphingomyelinase
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_2v3fd4529623mvk7nordsc0adj